Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy, safety, and risk stratification

Martina Catalano, Sara Bartoli, Alessia Salfi, Mirko Bonalda, Lorenzo Della Seta, Alexandra Paulet, Francesco Bloise, Federico Paolieri, Luca Galli, Michele Sisani, Laura Doni, Armando Perrella, Lorenzo Antonuzzo, Giandomenico Roviello

Therapeutic Advances in Urology

Published online on January 17, 2026

Abstract

Therapeutic Advances in Urology, Volume 18, January-December 2026.
Background:Enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, has demonstrated efficacy in advanced urothelial carcinoma (UC) following platinum-based chemotherapy and immune checkpoint inhibitor (ICI) therapy. However, real-world ...